Assessment and clinical implications of RANK/RANKL/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases

References

• Aapro M, Abrahamsson PA, Body JJ, et al. (2008). Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol, 19, 420–32
   PubMed Web of Science ®Google Scholar
• Bhatia P, Sanders MM, Hansen MF. (2005). Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma. Clinl Cancer Res, 11, 162–5
   PubMed Web of Science ®Google Scholar
• Body JJ. (2006). Bisphosphonates for malignancy-related bone disease: current status, future developments. Support Care Cancer, 14, 408–18
   PubMed Web of Science ®Google Scholar
• Boyce FB, Xing L. (2007). Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther, 9, S1
   PubMed Web of Science ®Google Scholar
• Chen G, Sircar K, Aprikian A, et al. (2006). Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer, 107, 289–98
   PubMed Web of Science ®Google Scholar
• Costa L, Major PP. (2009). Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nate Clin Pract Oncol, 6, 163–74
   PubMedGoogle Scholar
• Dougall WC, Chaisson M. (2006). The RANKL/RANK/OPG triad in cancer induced bone diseases. Cancer Metast Rev, 25, 541–9
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci MA, Smith MR, et al. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 5, 813–22
   Google Scholar
• Grimaud E, Soubigou L, Couillaud S, et al. (2003). Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol, 163, 2021–31
   PubMed Web of Science ®Google Scholar
• Henry DH, Costa L, Goldwasser F, et al. (2011). Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol, 20, 1125–32
   Google Scholar
• Hofbauer LC, Neubauer A, Heufelder AE. (2001). Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer, 92, 460–70
   PubMed Web of Science ®Google Scholar
• Jung K, Lein M, Stephan C, et al. (2004). Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer, 111, 783–91
   PubMed Web of Science ®Google Scholar
• Kaplan RN, Rafii S, Lyden D. (2006). Preparing the “soil”: the premetastatic niche. Cancer Res, 66, 11089–93
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, et al. (2008). Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol, 26, 2124–30
   PubMed Web of Science ®Google Scholar
• Lombard-Bohas C, Mitry E, O’Toole D, et al. (2009). Thirteen-month registration of patients with gastroenteropancreatic endocrine tumours in France. Neuroendocrinology, 89, 217–22
   Google Scholar
• Meijer WG, van der Veer E, Jager PL, et al. (2003). Bone metastases in carcinoid tumours: clinical features, imaging characteristics, and markers of bone metabolism. J Nucl Med, 44, 184–91
   Google Scholar
• Modlin IM, Lye KD, Kidd M. (2003). A 5-decade analysis of 13715 carcinoid tumours. Cancer, 97, 934–59
   PubMed Web of Science ®Google Scholar
• Mountzios G, Dimopoulos MA, Bamias A, et al. (2007). Abnormal bone remodeling process is due to an imbalance in the receptor activator of nuclear factor-kappaB ligand (RANKL)/osteoprotegerin (OPG) axis in patients with solid tumours metastatic to the skeleton. Acta Oncol, 46, 221–9
   PubMed Web of Science ®Google Scholar
• Murthy RK, Morrow PK, Theriault RL (2009). Bone biology and the role of the RANK ligand pathway. Oncology, 23, 9–15
   PubMed Web of Science ®Google Scholar
• Panzuto F, Nasoni S, Falconi M, et al. (2005). Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localisation. Endocr-Relat Cancer, 12, 1083–92
   PubMed Web of Science ®Google Scholar
• Pape UF, Berndt U, Müller-Nordhorn J, et al. (2008). Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr-Relat Cancer, 15, 1083–97
   PubMed Web of Science ®Google Scholar
• Polascik TJ, Mouraviev V. (2008). Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag, 4, 261–8
   PubMedGoogle Scholar
• Santini D, Berruti A, Bertoldo F, et al. (2009). AIOM guidelines for the treatment of bone metastases. preprint777–863
   Google Scholar
• Santini D, Galluzzo S, Zoccoli A, et al. (2010). New molecular targets in bone metastases. Cancer Treat Rev, 36, S6–10
   PubMed Web of Science ®Google Scholar
• Stopeck AT, Lipton A, Body JJ, et al. (2010). Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol, 10, 5132–9
   Google Scholar
• Strosberg J, Gardner N, Kvols L. (2009). Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the midgut. Neuroendocrinology, 89, 471–6
   PubMed Web of Science ®Google Scholar
• Terpos E, Szydlo R, Apperley JF, et al. (2003). Soluble receptor activator of nuclear factor kappaB ligand–osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood, 102, 1064–9
   PubMed Web of Science ®Google Scholar